Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for Rate Control in Permanent Atrial Fibrillation
NCT03987204Phase 1Completed
- Sponsor
- Yale University
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivabradine in Atrial fibrillation (AFib), sponsored by Yale University. Primary endpoints: Mean and Maximum Heart Rate in Daily Life at 2 weeks, Percent Pacing in Daily Life at 2 weeks and 2 more. Started Jun 2019; status: completed.
02
Drugs
ivabradine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03987204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987204.